Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus

NCT07348055 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07348055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
December 1, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

auto immune disease, systemic lupus erthematosus